# OnCo record adagrasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/adagrasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "adagrasib" ;
  schema:name "Adagrasib"@en ;
  schema:description "Adagrasib was the second KRAS G12C inhibitor, with a long half-life and brain penetration, and is approved in lung and colorectal cancer."@en ;
  schema:url <https://onco.cc/drugs/adagrasib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Adagrasib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q105816120> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Adagrasib>, <https://doi.org/10.1200/JCO.23.00434>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22KRAZATI%22>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications> ;
  onco:status "approved" ;
  onco:modality "Small-molecule inhibitor (KRAS G12C)" ;
  schema:alternateName "Krazati" ;
  onco:approval "US 2022: KRAS G12C NSCLC (accelerated)", "US 2024: KRAS G12C colorectal cancer with cetuximab", "EU 2024: KRAS G12C NSCLC after ≥1 line; 5 Jan 2024 (conditional)", "US 2024: KRAS G12C-mutated locally advanced or metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with cetuximab" ;
  onco:acceleratedApproval "US 2022-12-12: Adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.", "US 2024-06-01: In combination with cetuximab for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy." ;
  onco:related <https://onco.cc/biomarkers/kras-g12c/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-g12c-colorectal/>, <https://onco.cc/cancers/kras-g12c-nsclc/>, <https://onco.cc/cancers/kras-g12c-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct04613596/>, <https://onco.cc/trials/nct05853575/>, <https://onco.cc/trials/nct05609578/>, <https://onco.cc/trials/nct07415031/>, <https://onco.cc/trials/nct06875310/>, <https://onco.cc/trials/nct03785249/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/>, <https://onco.cc/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/>, <https://onco.cc/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/> .